GBIM:OTCMKTS
GlobeImmune Inc
0,00010 USD
0,00%
(0,00) 1 zi
29 sept., 15:48:52 GMT-4 · USD
search
Toate simbolurile
| Simbol | Preț | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru GBIM...
Capitalizarea bursieră
580,00
Volum mediu
1,74 K
Volum
0,00
Prețul ridicat pe 52 de săptămâni
0,04 USD
Prețul redus pe 52 de săptămâni
0,00 USD
Acțiuni aflate în circulație
5,75 mil.
Nr. de angajați
22
Capitalizarea bursieră
580,00
Volum mediu
1,74 K
Volum
0,00
Prețul ridicat pe 52 de săptămâni
0,04 USD
Prețul redus pe 52 de săptămâni
0,00 USD
Acțiuni aflate în circulație
5,75 mil.
Nr. de angajați
22
Subiecte de știri
Din surse web și de la parteneri de știri
Ziare.com
·
acum 10 ore
Pentru a doua oară în istorie: Bursa transmite un semnal de avertizare rar și indică apariția unor...
MarketBeat
·
acum 17 minute
X-Energy (NASDAQ:XE) Reaches New 12-Month Low - Time to Sell?
FXStreet
·
acum 38 de minute
Dow Jones futures advance as US Treasury yields, oil prices ease
Investor's Business Daily
·
acum 6 ore
Tech Futures Rise: Meta, AMD Lead 5 Buys; ASML, CPI Inflation Due
Profil
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Despre GlobeImmune Inc
Director executiv-
Angajați22
Înființată la1 ian. 1995
SediuLouisville, Colorado, Statele Unite ale Americii
Domeniu-
Siteglobeimmune.com